Experts Discuss Trend of De-Escalating Treatments in Breast Cancer at Recent Symposium
The world of oncology is constantly evolving, with new trends emerging that aim to provide more personalized and targeted treatments for patients. In recent years, the concept of “treatment in less” has gained popularity, particularly in the field of breast cancer treatment.
During the recent Multidisciplinary Symposium on Breast Cancer held in Buenos Aires, more than 500 specialists gathered to discuss the latest international research on de-escalating treatments in breast cancer. The symposium, organized by the Argentine Society of Mastology (SAM) and the Argentine Association of Clinical Oncology (AAOC), highlighted the importance of individualized treatment plans for each patient.
One of the key topics of discussion at the symposium was the possibility of reducing the intensity of treatments for patients with breast cancer, without compromising the final outcome. Studies have shown that in certain cases, less aggressive treatments can be just as effective as more intensive therapies.
For example, research has shown that in patients with small, node-negative breast cancer, omitting axillary surgery or sentinel lymph node biopsy may not negatively impact disease-free survival. Additionally, in certain cases, adjuvant chemotherapy may not be necessary for patients with triple-negative tumors or tumors smaller than five millimeters.
Dr. Francisco Terrier, the new president of SAM, emphasized the importance of risk-adapted treatment in breast cancer, where treatments are tailored to the individual patient’s needs. This approach allows for a more precise and personalized treatment plan, with the aim of both increasing cure rates and improving the patient’s quality of life.
Immunotherapy, which is gaining ground in the treatment of various cancers, was also highlighted at the symposium. The use of immunotherapy in conjunction with traditional chemotherapy drugs has shown promising results, leading to a reduction in chemotherapy doses in some cases.
Oncofertility, or the preservation of fertility in cancer patients, was another important topic discussed at the symposium. Young patients with positive BRCA genetic mutations were advised on fertility preservation options, as research has shown that pregnancy after breast cancer treatment can be safe in these patients.
Overall, the symposium provided valuable insights into the evolving landscape of breast cancer treatment, emphasizing the importance of individualized and targeted therapies for patients. As research continues to advance, the future of breast cancer treatment looks promising, with a focus on improving outcomes and quality of life for patients.